The short answer
No required MSM spacing or general avoidance rule with mefenamic acid is established. Review the full joint-supplement label and follow the prescription’s duration limits.
What this answer covers
Oral purified methylsulfonylmethane (MSM) with oral mefenamic acid capsules, explicitly bridged to mefenamate IN.
- Supplement or preparation
- Dimethyl sulfone
- Medication ingredient
- mefenamate
The MSM trial did not test this combination
A knee-osteoarthritis trial studied purified MSM for 12 weeks, with NSAID users undergoing a ten-day washout before enrollment. That design does not establish a safe interval between MSM and mefenamic acid doses or demonstrate harm from their combination.
Benefits and safety remain limited
Some symptom and function measures improved in the small MSM trial, but the authors considered the clinical importance uncertain. Allocation and baseline differences limit confidence. The study cannot establish long-term combination safety or justify replacing prescribed treatment.
Check what you are taking
The tested product supplied 3.375 g of purified MSM daily. Multi-ingredient joint supplements may contain additional botanicals or pain relievers with separate concerns. Show the full label to the pharmacist and avoid treating similarly named sulfur-containing substances as equivalent.
Follow the prescription’s treatment limits
The mefenamic acid label limits acute-pain treatment to no more than seven days and also covers primary dysmenorrhea. Review ongoing pain with the prescriber rather than extending treatment because a supplement was added. Seek urgent assessment for signs of GI bleeding.
Evidence and practical considerations
Timing & monitoring
A required separation interval or general avoidance rule for MSM with mefenamic acid has not been established.
- Exact scope
- Oral purified methylsulfonylmethane (MSM) with oral mefenamic acid capsules, explicitly bridged to mefenamate IN. with Exact mefenamate IN 257844 linked by current RxNorm to mefenamic acid PIN 6693. The inspected oral acid capsules supply the explicit ingredient bridge, not meclofenamate or a different fenamate.
- Medication form and route
- Oral
What remains uncertain
- MSM trial required NSAID washout before enrollment, not a tested coadministration interval. Sulfur-containing names do not establish a shared interaction.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Prescription oral oral mefenamic acid 250 mg capsules users; short human pharmacology studies where described.
Short-term acute pain up to seven days and primary dysmenorrhea indications. Serious GI warnings; magnesium hydroxide raises peak concentration and AUC in a small human study.
How this applies: Exact current product label. Exact mefenamate IN 257844 linked by current RxNorm to mefenamic acid PIN 6693. The inspected oral acid capsules supply the explicit ingredient bridge, not meclofenamate or a different fenamate.
Exact oral product label; no measured botanical co-use incidence. Ingredient, route, preparation and comparator differences must be retained.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 50 adults with knee osteoarthritis assigned to MSM or placebo.
Some symptom/function measures improved, but the authors judged improvements small and of uncertain clinical importance.
How this applies: Indirect for oral mefenamic acid 250 mg capsules co-use; exact preparation and endpoint retained.
Full original body inspected. Predictable allocation, baseline imbalance and limited safety assessment. Concurrent anticoagulant/antiplatelet users excluded; not a mefenamic-acid interaction or spacing study.
Source 3: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
mefenamate is IN. Exact mefenamate IN 257844 linked by current RxNorm to mefenamic acid PIN 6693. The inspected oral acid capsules supply the explicit ingredient bridge, not meclofenamate or a different fenamate.
How this applies: Exact identity.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: a6159273bf340d13
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.